Get the Stockscreener App
4.82
0.00%
0.00
Mimedx Group Inc stock is traded at $4.82, with a volume of 427.28K.
It is up +0.00% in the last 24 hours and down -4.17% over the past month.
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
See More
Previous Close:
$4.82
Open:
$4.77
24h Volume:
427.28K
Relative Volume:
0.48
Market Cap:
$705.71M
Revenue:
$342.81M
Net Income/Loss:
$97.67M
P/E Ratio:
7.8438
EPS:
0.6145
Net Cash Flow:
$50.46M
1W Performance:
-2.43%
1M Performance:
-4.17%
6M Performance:
-32.49%
1Y Performance:
-40.38%
1-Day Range:
$4.74
$4.87
1-Week Range:
$4.70
$4.99
52-Week Range:
$4.70
$8.20
Mimedx Group Inc Stock (MDXG) Company Profile
Name
Mimedx Group Inc
Sector
Industry
Phone
(770) 651-9100
Address
1775 W OAK COMMONS COURT, NE, MARIETTA
Compare MDXG vs MOBBW, SHMD, GOODO, PSNYW, DWLD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| 6.49 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
2.1602 | 2.87B | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
7.16 | 465.95M | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
20.26 | 372.90M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
3.1578 | 350.59M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
DWLD
Davis Select Worldwide ETF
|
45.07 | 0 | 0 | 0 | 0 | 0.00 |
Mimedx Group Inc Stock (MDXG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-02-24 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-07-24 | Initiated | Lake Street | Buy |
| Oct-27-23 | Initiated | Craig Hallum | Buy |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Jul-26-21 | Initiated | Northland Capital | Outperform |
| Mar-19-21 | Initiated | H.C. Wainwright | Buy |
View All
Mimedx Group Inc Stock (MDXG) Latest News
MiMedx (MDXG) Launches New AMNIOFIX Thyroid Shields - GuruFocus
Thyroid surgery shield shows 76% drop in vocal nerve damage in study - Stock Titan
MiMedx Group (NASDAQ:MDXG) Sets New 1-Year LowWhat's Next? - MarketBeat
The Rosen Law Firm Files Securities Fraud Class Action Against MiMedx Group, Inc.MDXG - Yahoo
MiMedx Group, Inc (MDXG) Stock Analysis: A Biotech Powerhouse with Nearly 100% Upside Potential - DirectorsTalk Interviews
InvestingPro Fair Value flagged MiMedx as overvalued before 47% drop By Investing.com - Investing.com Canada
Global Placenta Extract Market Size, Growth, Trends & Forecast to 2033 telaGen, BIOON, MiMedx Group - openPR.com
MiMedx Group (MDXG) Delivers Record Full Year Revenue - Finviz
MiMedx Group (NASDAQ:MDXG) Downgraded by Wall Street Zen to Buy - MarketBeat
Q2 EPS Estimates for MiMedx Group Lowered by Analyst - MarketBeat
MiMedx Group (NASDAQ:MDXG) Reaches New 1-Year LowWhat's Next? - MarketBeat
MiMedx Group (NASDAQ:MDXG) Stock Price Down 8.8%Here's What Happened - MarketBeat
MiMedx Group (MDXG) Revenue Jump To US$118.1 Million Tests Slow Growth Narrative - Sahm
MiMedx Group Q4 Earnings Call Highlights - Yahoo Finance
Transcript : MiMedx Group, Inc., Q4 2025 Earnings Call, Feb 25, 2026 - marketscreener.com
Earnings call transcript: MiMedx Q4 2025 sees robust growth, EPS beats forecast - Investing.com UK
MIMEDX Announces Record Fourth Quarter and Full Year 2025 Operating and Financial Results - The Globe and Mail
MiMedx (MDXG) Q4 Earnings and Revenues Beat Estimates - Nasdaq
MiMedx Group (NASDAQ:MDXG) Issues Quarterly Earnings Results, Beats Expectations By $0.05 EPS - MarketBeat
MIMEDX Group Inc (NASDAQ:MDXG) Stock Dips Despite Strong Earnings Beat - ChartMill
MiMedx (MDXG) Q4 2025 Earnings Call Transcript - AOL.com
MiMedx: Q4 Earnings Snapshot - marketscreener.com
Earnings Flash (MDXG) MiMedx Group, Inc. Posts Q4 Adjusted EPS $0.14 per Share, vs. FactSet Est of $0.09 - marketscreener.com
Earnings Flash (MDXG) MiMedx Group, Inc. Reports Q4 Revenue $118.1M, vs. FactSet Est of $106.8M - marketscreener.com
MiMedx (MDXG) details wound-care expansion, new products and Medicare shifts - Stock Titan
MiMedx Group, Inc. announces an Equity Buyback for $100 million worth of its shares. - marketscreener.com
What to Expect from MiMedx Group's Earnings - Benzinga
MiMedx Group Inc (MDXG) Q4 2025 Earnings Report Preview: What to Look For - GuruFocus
MiMedx Group, Inc (MDXG) Stock Analysis: Exploring an 81% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
MiMedx Group (MDXG): Citizens Initiates Coverage with Market Out - GuruFocus
MiMedx Group (NASDAQ:MDXG) Now Covered by Citizens Jmp - MarketBeat
MiMedx Group, Inc (NASDAQ:MDXG) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Beyond The Numbers: 4 Analysts Discuss MiMedx Group Stock - Benzinga
This MiMedx Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Citizens Initiates Coverage of MiMedx Group (MDXG) with Market Outperform Recommendation - Nasdaq
Citizens initiates MiMedx stock with outperform on reimbursement outlook By Investing.com - Investing.com Canada
Citizens initiates MiMedx stock with outperform on reimbursement outlook - Investing.com
How The MiMedx (MDXG) Investment Story Is Resetting Around CMS And Analyst Revisions - Yahoo Finance
MiMedx Group, Inc. authorizes a Buyback Plan. - marketscreener.com
What catalysts could drive MiMedx Group Inc. stock higherJuly 2025 Market Mood & Breakout Confirmation Trade Signals - mfd.ru
MSN Money - MSN
Will MiMedx Group Inc. stock benefit from AI adoption2025 Dividend Review & AI Forecasted Entry and Exit Points - mfd.ru
Stem Cell and Regenerative Therapy Markets, 2022-2025 & - GlobeNewswire
Stem Cell and Regenerative Therapy Markets, 2022-2025 & Forecast to 2030 Featuring Profiles of Leading CompaniesGilead Sciences, Novartis, Bristol-Myers Squibb, Organogenesis, MiMedx Group and More - Yahoo Finance
Aug Swings: What’s the MACD signal for MiMedx Group Inc.Weekly Profit Summary & Safe Capital Growth Plans - mfd.ru
Is MiMedx Group Inc. stock a good pick for beginnersBuy Signal & Daily Stock Trend Reports - mfd.ru
MiMedx (NASDAQ: MDXG) COO reports 61,961-share tax withholding on vesting - Stock Titan
MiMedx Group (MDXG) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Cantor Fitzgerald Issues Pessimistic Forecast for MiMedx Group (NASDAQ:MDXG) Stock Price - MarketBeat
MiMedx Group, Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026 - Quiver Quantitative
MiMedx Group, Inc (MDXG) Stock Analysis: A Biotech Gem With An 87.5% Potential Upside - DirectorsTalk Interviews
Mimedx Group Inc Stock (MDXG) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):